Aripiprazole lauroxil is primarily used in the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults. It is administered as a long-acting injectable formulation, providing sustained release of the active ingredient over an extended period. This makes it particularly beneficial for patients who have difficulty adhering to daily oral medication regimens. The extended-release nature of the injection helps maintain consistent therapeutic levels of the drug in the body, reducing the risk of relapse and improving overall symptom management. It is typically administered once every four to six weeks by a healthcare professional, offering a convenient option for long-term maintenance therapy. Additionally, it is used to manage acute episodes of schizophrenia and to prevent the recurrence of symptoms in stabilized patients. Its use is often considered for individuals who have responded well to oral aripiprazole but require a more manageable treatment option to ensure compliance and continuity of care.